Pepse (HIV Post-Exposure Prophylaxis)

Pepse is the common term used in various regions, particularly the UK and parts of Europe, to refer to a specific course of antiretroviral medication used for Post-Exposure Prophylaxis (PEP) after potential sexual exposure to HIV. While not a brand name itself, it is a clinical designation for the emergency treatment regimen. The medication combination typically prescribed involves three drugs, most commonly Tenofovir disoproxil and Emtricitabine (often as the brand Truvada or generic equivalents) combined with a third agent like Raltegravir (brand name Isentress) or Dolutegravir (brand name Tivicay).

The regimen was developed through clinical guidelines by organizations such as the British Association for Sexual Health and HIV (BASHH). Because Pepse refers to a combination therapy, the individual medications are manufactured by various global pharmaceutical giants including Gilead Sciences, Viiv Healthcare, and GSK, along with several generic manufacturers in countries such as India and the United States. Today, the choice of the PEPSE regimen remains a critical part of public health strategies to prevent HIV seroconversion following high-risk incidents.